



Advances in Urogenital Pathology

Guest Editors:

Dr. José I. López

Biobizkaia Health Research
Institute, 48903 Barakaldo, Spain

Dr. Claudia Manini

Department of Pathology, San
Giovanni Bosco Hospital, 10154
Turin, Italy

Deadline for manuscript
submissions:

closed (15 April 2022)

Message from the Guest Editors

The urogenital system, from the kidney to the penis, involves what is likely the widest spectrum of inflammatory, infectious, reactive, and neoplastic entities ever collected along the human body. Kidney, urinary tract, and prostate tumors are neoplasms frequently seen in daily practice, and their clinical management includes several of the most advanced examples of personalized medicine. Actually, new developments in therapies focusing on antiangiogenic, immune checkpoint blockage, and hormonal resistance are current hot topics in modern oncology. On the other hand, the non-neoplastic pathology in this field is frequent and varied, from malformations to reactive-inflammatory conditions and post-surgical complications, in which the latest technological developments deserve attention.

This Special Issue intends to serve as a multidisciplinary forum where urologists, medical oncologists and radiotherapists, as well as nuclear medicine specialists, pathologists, radiologists and other specialists, can meet to improve patient care.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)